Verastem Oncology
117 Kendrick Street
Suite 500
Needham
MA
02494
United States
Tel: (718) 292-4200
Website: http://www.verastem.com/
Email: info@verastem.com
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
Founded: 2010
372 articles with Verastem Oncology
-
Verastem, Inc. to Present at Biotechnology Industry Organization (BIO) CEO and Leerink Swann and Company Conferences
2/9/2012
-
Verastem, Inc. Release: Underwriters Exercise Over-Allotment Option for Verastem Initial Public Offering
2/2/2012
-
Verastem, Inc. Bucks the Trend, Raises $55 Million in IPO
1/27/2012
-
Verastem, Inc. 4.5 Million-Share IPO Seen Pricing at $9-$11 a Piece
1/17/2012
-
Verastem, Inc., With IPO Planned, Raises $20 Million in Funding
11/11/2011
-
Verastem, Inc. Braves the Public Market, Files for $50 Million IPO
11/3/2011
-
Verastem, Inc. Appoints José Baselga, M.D., Ph.D., to Scientific Advisory Board
9/8/2011
-
Verastem, Inc. to Present at the Stifel Nicolaus 2011 Healthcare Conference
9/1/2011
-
Verastem, Inc. Appoints Jonathan Pachter as Head of Research
8/4/2011
-
Verastem, Inc. Nabs $32 Million Series B Financing
7/14/2011
-
Verastem, Inc. to Present at 2011 CEO Biotech Conference
6/15/2011
-
Biotech To Beat The Summer Blahs
7/6/2004